Business Description
Galectin Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US3632252025
Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | -3.19 | |||||
| Debt-to-Equity | -1.13 | |||||
| Debt-to-EBITDA | -2.59 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -15.9 | |||||
| 3-Year EPS without NRI Growth Rate | -21.4 | |||||
| 3-Year FCF Growth Rate | -14.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -23.21 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.91 | |||||
| 9-Day RSI | 15.72 | |||||
| 14-Day RSI | 19.85 | |||||
| 6-1 Month Momentum % | 30.69 | |||||
| 12-1 Month Momentum % | 82.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.13 | |||||
| Quick Ratio | 1.13 | |||||
| Cash Ratio | 1.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 | |||||
| Shareholder Yield % | -48.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -169.62 | |||||
| ROIC % | -1119.83 | |||||
| ROCE % | -373.01 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -3.76 | |||||
| EV-to-EBITDA | -3.76 | |||||
| EV-to-Forward-Revenue | 4.18 | |||||
| EV-to-FCF | -4.51 | |||||
| Earnings Yield (Greenblatt) % | -26.6 | |||||
| FCF Yield % | -46.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galectin Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.67 | ||
| Beta | 0.94 | ||
| Volatility % | 74.02 | ||
| 14-Day RSI | 19.85 | ||
| 14-Day ATR (€) | 0.133864 | ||
| 20-Day SMA (€) | 1.73475 | ||
| 12-1 Month Momentum % | 82.07 | ||
| 52-Week Range (€) | 0.82 - 3.8 | ||
| Shares Outstanding (Mil) | 62.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galectin Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galectin Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Galectin Therapeutics Inc Frequently Asked Questions
What is Galectin Therapeutics Inc(STU:PHPN)'s stock price today?
The current price of STU:PHPN is €0.87. The 52 week high of STU:PHPN is €3.80 and 52 week low is €0.82.
When is next earnings date of Galectin Therapeutics Inc(STU:PHPN)?
The next earnings date of Galectin Therapeutics Inc(STU:PHPN) is 2025-03-28 Est..
Does Galectin Therapeutics Inc(STU:PHPN) pay dividends? If so, how much?
Galectin Therapeutics Inc(STU:PHPN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers